N/A N=27 Multicomponent Behavioral Sleep Intervention for Insomnia in Older Adults With Mild Cognitive Impairment
Mild Cognitive Impairment · Insomnia
Primary: Sleep Latency — 28.51; 47.06 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=7 Sleep Well 24 (SWELL24) Healthy Sleep-Wake Behaviors in Older Adults
Insomnia Disorder
Primary: Sleep Efficiency — 95.1 percent
Phase 4 N=388 A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia
Insomnia
Primary: Mean Change From Baseline in Subject-Reported Total Sleep Time (TST) Averaged Over the 12 Week Double Blind Study Period. — 33.18; 63.24 minutes — p=<0.0001
Phase 3 N=538 Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)
Insomnia · Sleep Initiation and Maintenance Disorders · Mental Disorders
Primary: Average Wake Time After Sleep Onset Measured by Polysomnography — 80.3; 79.6; 74.8; 109.8 Minutes — p=<0.0001
Phase 3 N=30 Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Parkinson's Disease · Insomnia
Primary: TST — 5.7; 6.0 hours
Phase 4 N=79 Improving Sleep in Nursing Homes
Sleep Deprivation
Primary: Number of Participants Meeting Good Sleep Latency Criteria — 7; 6 participants — p=0.655
Phase 4 N=115 Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia
Insomnia · Insomnia Chronic
Primary: Treatment Response (Phase 1) — 94 Participants
Phase 2 N=112 Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia
Chronic Primary Insomnia
Primary: Mean Wake Time After Sleep Onset (WASO) — 109.1; 98.7; 90.0; 77.7 minutes — p=0.0018
N/A N=200 SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid
Insomnia
Primary: Continuous Performance Test (CPT) — 56.2; 55.8 T-Score
N/A N=154 Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes
Menopause
Primary: Diary Based Sleepiness — 5.01; 5.13; 4.87; 4.72 score on a scale
N/A N=92 Improving Sleep Using Mentored Behavioral and Environmental Restructuring
Insomnia
Primary: Sleep Efficiency (SE) — 76.1 percentage of time in bed
Phase 2 N=58 Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder
Insomnia Disorder
Primary: Change in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2 — -18.9; -32.0; -45.1; -61.4 minutes — p=<0.001
Phase 3 N=325 A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)
Insomnia
Primary: Incidence of Adverse Events — 81.5; 79.5; 82.1; 87.0 Percentage of Participants
Phase 3 N=27 Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375)
Insomnia · Obstructive Sleep Apnea
Primary: Sleep Onset Latency — 9.7; 34.4 minutes
N/A N=30 SleepSMART for Veterans With MCI and Insomnia
Insomnia · Mild Cognitive Impairment
Primary: Client Satisfaction Questionnaire (CSQ-8) — 29.43 score on a scale
Phase 3 N=1,006 Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)
Insomnia
Primary: Change From Baseline in Mean Latency to Persistent Sleep (LPS) of Lemborexant 10 mg and Lemborexant 5 mg Compared to Placebo on Days 29/30 — 43.89; 44.86; 44.61; -7.93…
N/A N=159 Implementing Sleep Interventions for Older Veterans
Insomnia
Primary: Sleep Onset Latency — 21.3; 31.3 Minutes — p=<.001
N/A N=46 Individually Tailored Lighting System to Improve Sleep in Older Adults
Sleep Disturbances
Primary: Sleep Disturbance — -1.9; -1.3 units on a scale
N/A N=30 Chronic Insomnia and CSF Markers of Dementia
Insomnia Chronic
Primary: CSF Markers Related to Dementia — 4332.1; 4824.0; 393.2; 419.4 picograms per milliliter
Phase 3 N=460 A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)
Sleep Initiation and Maintenance Disorders · Mental Disorders · Dyssomnias
Primary: Change From Baseline in Total Sleep Time (TST) - 6-Month Treatment Period — 65.9; 19.3 minutes — p=<0.0001
N/A N=137 Sleep Specialty Consultation: Improving Management of Sleep Disorders
Sleep Disorders
Primary: Provider Adherence to Sleep Specialist Recommendations — 4; 0; 8; 4 participants
N/A N=188 Sleep Without Insomnia or The Use of Chronic Hypnotics
Sleep Initiation and Maintenance Disorders
Primary: Rates of Hypnotic Discontinuation — 64; 52 Participants — p=.039
Phase 4 N=100 Suvorexant and Sleep/Delirium in ICU Patients
Insomnia · Sleep Fragmentation · Sleep Initiation and Maintenance Disorders
Primary: Nighttime Wakefulness After Persistent Sleep Onset (WASO) — 200.7; 184.2 minutes
Phase 2 N=40 Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes
Insomnia
Primary: Change in Daytime Insomnia Symptoms Scale (DISS) — 65.96; 70.34; 69.22; 72.32 units on a scale
N/A N=92 Determinants of Age Related Breathing Instability During Non-Rapid-Eye-Movement (NREM) Sleep
Sleep Apnea · Age
Primary: Apneic Threshold (AT) and Carbon-dioxide (CO2) Reserve — 39.8; 36.7; -4.1; -2.6 mm Hg — p=<0.05
Phase 3 N=259 A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)
Sleep Initiation and Maintenance Disorder; Elderly · Mental Disorder · Dyssomnias
Primary: Number of Participants Who Experience at Least One Adverse Event (AE) — 115; 116 Participants
Phase 2 N=67 Study of Sleep-maintenance Activity of 3 Doses of SKP-1041
Sleep Disorder · Primary Insomnia
Primary: Wake After Sleep Onset During Hours 3 to 7 Post-dose (WASO 3-7) — -40.19; -48.79; -50.17; -49.34 minutes — p=0.0118
N/A N=245 The RESTING Insomnia Study: Randomized Controlled Study on Effectiveness of Stepped-Care Sleep Therapy
Insomnia
Primary: Insomnia Severity Index (ISI) — 15.9; 15.4; 12.7; 11.6 score on a scale — p=0.001
Phase 2 N=137 Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients
Primary Insomnia
Primary: Latency to Persistent Sleep — -22.7; -39.1; -37.5 minutes
N/A N=211 Sequenced Therapies for Comorbid and Primary Insomnias
Insomnia Comorbid to Psychiatric Disorder · Primary Insomnia
Primary: Percent of Participants Who Met Remission as Measured by the Insomnia Severity Index — 40.00; 34.94; 37.04; 48.15 percent remitted